 | | Vol. 12.32 – 20 August, 2020 |
| |
|
|
| Investigators designed an αHER2 antibody–sialidase conjugate that potently and selectively stripped diverse sialoglycans from breast cancer cells.
[Nature Chemical Biology] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Single‐cell RNA sequencing of five TNBCs revealed two cancer‐associated fibroblast (CAF) and two perivascular‐like (PVL) subpopulations. CAFs clustered into two states: the first with features of myofibroblasts and the second characterised by high expression of growth factors and immunomodulatory molecules.
[EMBO Journal] |
|
|
|
| Researchers report that AGO1x, an evolutionarily conserved translational readthrough isoform of Argonaute 1, was generated in highly proliferative breast cancer cells, where it curbed accumulation of double‐stranded RNAs (dsRNAs) and consequent induction of interferon responses and apoptosis.
[EMBO Journal] |
|
|
|
| Scientists found that aquaporin1 and glycogen synthase kinase-3β competitively interacted with the 12 armadillo repeats of β-catenin, followed by the inhibition of the β-catenin degradation that led to β-catenin’s accumulation in the cytoplasm and nuclear translocation.
[Cell Death & Differentiation] |
|
|
|
| Phosphoglycerate dehydrogenase (PHGDH) was degraded by the E3 ubiquitin ligase, RNF5, to prevent the proliferation of breast cancer cells. The acetylation of PHGDH at K58 disrupted the interaction of RNF5-PHGDH and promoted the proliferation of breast cancer cells.
[Cell Reports] |
|
|
|
| Ex vivo human breast cancer tissue cultures retained original tissue architecture, epithelial and stromal cell components and estrogen receptor α (ERα).
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers found that miR-93-5p (miR-93) significantly inhibited cell proliferation, induced G1/S cell cycle arrest and increased chemosensitivity to paclitaxel in vitro and in vivo.
[Cell Death & Disease] |
|
|
|
| A novel ceRNA network of LRRC75A-AS1/miR-380–3p/BAALC accelerated TNBC development.
[Cell Death & Disease] |
|
|
|
| Scientists showed that P2X purinoceptor 7 (P2X7) receptor was functional in highly aggressive mammary cancer cells, and induced a change in cell morphology with fast F-actin reorganization and formation of filopodia, and promoted cancer cell invasiveness through both two- and three-dimensional extracellular matrices in vitro.
[Cancers] |
|
|
|
| RelB promoted breast cancer cell proliferation through increased G1/S transition and/or decreased apoptosis by upregulation of Cyclin D1 and Bcl-2. RelB upregulated bone metastatic protein MMP1 expression through binding to an NF-κB enhancer element located at the 5′-flanking region.
[Cell Communication and Signaling] |
|
|
|
| Investigators report the establishment and characterization of a bone-seeking variant of breast cancer cells that spontaneously formed aggressive bone metastases following surgical resection of primary tumor.
[Scientific Reports] |
|
|
|
| TNBC cell line MDA-MB-468 with a GI50 value of 100 nM was greater than 500-fold more sensitive to NAP-6 compared with other tumor derived cell models. Within one hour exposure of these cells to NAP-6, CYP1A1 expression increased 25-fold, rising to 250-fold by 24 hours.
[Scientific Reports] |
|
|
|
|
| The authors highlight the findings on interferon-stimulated gene 15 and protein ISGylation, and their implications in the field of breast cancer research.
[Human Cell] |
|
|
|
|
| Shanghai Henlius Biotech, Inc. announced that the trastuzumab biosimilar Zercepac®, developed and manufactured by Henlius independently, had been approved by the National Medical Products Administration (NMPA).
[Henlius Biotech, Inc.] |
|
|
|
|
| November 5- 6, 2020
Virtual |
|
|
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Myeloid Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | University of Miami Sylvester Comprehensive Cancer Center – Miami, Florida, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
